Feb

2012

CeNeRx BioPharma, Inc.: Series D $4.6M

Posted in I - Series C, Q - 4Q11, R - SOUTH EAST, X - Anxiety, X - CNS, X - Depression, XX - NC

CeNeRx (Cary, NC) a clinical-stage biopharmaceutical company focused on diseases of the central nervous system, depression and anxiety, closed a $4.6M Series D financing. Participants include Aisling Capital, L Capital Partners, Perseus Soros Biopharmaceutical Fund, Omega Funds and Pappas Ventures.

Feb

2012

Pivot Medical, Inc.: Series C $32M

Posted in I - Series C, Q - 4Q11, R - WEST, X - Device (Orthopedic), XX - CA

Pivot Medical (Sunnyvale, CA) a clinical-stage device company focused on minimally invasive hip restoration technologies, closed a $32M Series C financing. Participants include Adams Street Partners, Delphi Ventures, Montreux Equity Partners and Ivy Capital Partners.

Jan

2012

Excelimmune, Inc.: Series C $12M

Posted in I - Series C, Q - 4Q11, R - NORTH EAST, X - Antibody, X - Antiinfective, X - MRSA, X - Oncology, XX - MA

Excelimmune (Woburn, MA) a preclinical-stage biopharmaceutical company focused on a recombinant polyclonal antibody platform for the treatment of infectious disease, closed a $12M Series C financing. Participants were not identified.

Jan

2012

Cytoo, SA: Series C $10M

Posted in I - Series C, Q - 4Q11, R - INTERNATIONAL, X - Device (Cell Assay)

Cytoo (Grenoble, FRA) a commercial-stage medical device company focused on cell based assays, high content analysis and cell screening, closed a $10M Series C financing. Participants include Sham, Entrepreneurs Fund and Auriga Ventures.

Jan

2012

Agios Pharmaceuticals, Inc.: Series C $78M

Posted in I - Series C, Q - 4Q11, R - NORTH EAST, X - Metabolism, X - Oncology, XX - MA

Agios Pharmaceuticals (Cambridge, MA) a clinical-stage biopharmaceutical company focused on cancer metabolism, closed a $78M Series C financing. Participants have included Celgene, ARCH Venture Partners, Flagship Ventures and Third Rock Ventures.

Jan

2012

PolyTherics, Ltd.: Series C $3.5M

Posted in I - Series C, Q - 3Q11, R - INTERNATIONAL, X - Biochem, X - GlycoBiology

PolyTherics (United Kingdom) a preclinical-stage biochemistry company focused on pegylation technologies, closed a $3.5M Series C financing. Participants include Beringea, Imperial Innovation and The Capital Fund.
Thanx for your patience as we catch-up.

Jan

2012

Zafgen, Inc.: Series C $33M

Posted in I - Series C, Q - 3Q11, R - NORTH EAST, X - Obesity, XX - MA

Zafgen (Cambridge, MA) a clinical-stage biopharmaceutical company focused on small molecule therapeutics for the treatment of obesity, closed a $33M Series C financing. Participants include Atlas Venture and Third Rock Ventures.
Thanx for your patience as we catch-up.

Jan

2012

Monteris Medical, Inc.: Series C $8.6M

Posted in I - Series C, Q - 3Q11, R - INTERNATIONAL, X - Device (Oncology)

Monteria Medical (Canada) a development-stage medical device company focused on laser interstitial thermal therapy for the treatment of brain tumors, closed a $8.6M Series C financing. Participants include Business Development Bank of Canada and Southwest Michigan First.
Thanx for your patience as we catch-up.

Jan

2012

NABsys, Inc.: Series C $10M

Posted in I - Series C, Q - 3Q11, R - NORTH EAST, X - Device (Sequencing), XX - RI

NABsys (Providence, RI) a development stage dna sequencing company focused on nanopore arrays that can do not require amplification or labeling, closed a $10M Series C financing. Participants include Stata Venture.
Thanx for your patience as we catch-up.

Jan

2012

Avedro, Inc.: Series C $25M

Posted in I - Series C, Q - 3Q11, R - NORTH EAST, X - Device (Ophthalmology), X - Opthalmology, XX - MA

Averdo (Waltham, MA) a commercial-stage ophthalmology medical device company focused on procedures for biomechanically strengthening and modifying the cornea, closed on $25M Series C financing. Participants include SCP Vitalife, Aperture Venture Partners, Prism VentureWorks, De Novo Ventures, Flagship Ventures, Borealis Ventures and Echelon Ventures.
Thanx for your patience as we catch-up.

Jan

2012

OPX Biotechnologies, Inc.: Series C $36.5M

Posted in I - Series C, Q - 3Q11, R - ROCKY MOUNTAIN, X - BioAcrylic, X - Biofuel, XX - CO

OPX Biotechnologies (Boulder, CO) a development-stage biofuels company using synthetic biology to engineer the microbes as a bio-acrylic renewable fuel source, closed a $36.5M Series C financing. Participants include US Renewables Group, DBL Investors, Mohr Davidow Ventures, Braemar Energy Ventures, Altira Group and X/Seed Capital.
Thanx for your patience as we catch-up.

Jan

2012

Horizon Discovery, Ltd.: Series C $18.6M

Posted in I - Series C, Q - 3Q11, R - INTERNATIONAL, X - Device (Diagnostic)

Horizon Discovery (United Kingdom) a commercial-stage translational genomics company focused on drug discovery and molecular diagnostics, closed a $18.6M Series C financing. Participants include MVM Life Sciences, DFJ Esprit and Roche Venture Fund.
Thanx for your patience as we catch-up.

Jan

2012

Restoration Robotics, Inc.: Series C $41M

Posted in I - Series C, Q - 3Q11, R - WEST, X - Device (Hair Loss), X - Hair Loss, XX - CA

Restoration Robotics (Mountain View, CA) a clinical-stage medical device company focused on computer assisted image-guidance for hair follicle harvesting, closed a $41M Series C financing. Participants include Clarus Ventures, Sutter Hill Ventures, Alloy Ventures and Interwest.
Thanx for your patience as we catch-up.

« Previous Entries

to top of page...